Kornimate/medical-research-clean huggingface dataset:
the efficacy and safety of intradermal acupuncture for acute herpes zoster

Conditions: Herpes Zoster

Summary: herpes zoster (hz), also commonly known as shingles, is characterized by a bandlike rash in the dermatome that corresponds to the affected nerve. pain is prevalent in hz patients, which may be provoked by light touch. postherpetic neuralgia (phn) is one of the most common complications of hz and it is generally intractable to treat. at present, common treatment methods for hz include anti-inflammatory, antiviral, analgesic, and neuroleptic regimens. nevertheless, the application of these therapies can sometimes be limited by side effects. in this scenario, it is urgent to seek alternative non-pharmacological therapies for treating hz. intradermal acupuncture (ida) is a common type of acupuncture. by retaining the needles for a much longer duration than other common modalities of acupuncture, ida can prolong the sustained effect of acupuncture. in addition, characterized by mild pain during the insertion of intradermal needles, ida is more suitable for patients who fear conventional acupuncture and it is also easy to operate by practitioners. therefore, concerning the treatment of pain conditions, such as acute hz, it may have certain advantages over conventional acupuncture. thus, the aim of this trial is to evaluate the efficacy and safety of ida for acute hz.

this randomized controlled trial will enroll 72 eligible patients with acute herpes zoster. participants who are confirmed eligibility will be randomly allocated to either the ida group or the sham ida group in a 1:1 ratio. the duration of the trial will include two study phases, including a 1-month intervention phase and a 3-month follow-up phase.

Eligibility criteria:
inclusion criteria: 1. participants have confirmed diagnosis of herpes zoster; 2. herpes zoster is in the acute stage and participants have not yet received antiviral treatment or analgesic treatment; 3. 18≤age≤80 years, regardless of gender; 4. significant pain with a visual analog scale (vas) score ≥ 4; 5. absence of other diseases causing skin temperature change; 6. participants can understand the study procedure and agree to sign the informed consent form. exclusion criteria: 1. participants have some specific types of herpes zoster, such as disseminated herpes zoster; or herpes zoster is located on regions that are not suitable for intradermal acupuncture, such as the head, face, or perineum. 2. pregnant or lactating subjects; 3. participants have scar constitution or have severe cardiovascular, hepatic, renal, and hematopoietic system diseases that result in bleeding tendency, thereby making them unsuitable for intradermal acupuncture; 4. participants with severe cognitive impairment who are unable to fully understand the trial protocol; 5. participants are taking part in other trials.

Keywords: herpes zoster intradermal acupuncture infrared thermography clinical trial
cd patients immune status evaluation

Conditions: Severe Crohn's Diease

Summary: using single cell sequencing method to evaluate and compare the immune status of patients with severe cd.


Eligibility criteria:
inclusion criteria: 1, patients with severe cd（cdai\>16,ses-cd\>19） 2, patients have no previous any drug therapy targeting cd or just received treatment of 5-asa - exclusion criteria: 1, patients have previous treatment of prednisone, immunosuppressive agents such as azathioprine and biologic agents such as infliximab 2, patients were diagnozed as mild-moderate cd 3, patients have other immune disordered diseases such as sle, pbc, aih, psc, sjogren syndrome, ulcerative colitis, and so on. -

Keywords: singcel cell sequencing
pre transplantation melanoma

Conditions: Malignant Melanoma

Summary: melanoma incidence is increase in global population and number of transplantation also. however immunosuppressor increase recurrence risk of melanoma. there are more and more cases of eligible patients to transplant with an antecedent of melanoma. there is no guideline yet. main objective is survival time without melanoma recurrence in this population to do guideline of time limit or not between melanoma and transplantation by stage.


Eligibility criteria:
inclusion criteria: * patient with an antecedent of melanoma before transplantation * not opposite to participate exclusion criteria: * under the age of 18 * patient under guardianship * patient not affiliated with a health system
a study evaluating ab248 alone or in combination with pembrolizumab in adult patients with solid tumors

Conditions: Solid Tumor; Non Small Cell Lung Cancer; Melanoma; Squamous Cell Carcinoma of Head and Neck; Renal Cell Carcinoma

Summary: this is a phase i, first-in-human (fih), open-label study to evaluate the safety, tolerability, pharmacokinetic (pk) profile, and preliminary efficacy of ab248 as monotherapy or in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. the study will consist of a dose escalation and a dose expansion stage.


Eligibility criteria:
inclusion criteria: * age ≥18 years of age at the time consent is signed. * has adequate end organ function per laboratory testing. * pregnancy prevention requirements * has measurable disease per recist 1.1 as assessed by the local site investigator/radiology. * has a performance status of 0 or 1 on eastern cooperative oncology group scale. * histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts exclusion criteria: * has a diagnosis of immunodeficiency. * has a history of a previous, additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years. * has known active cns metastases and/or carcinomatous meningitis. * has an active autoimmune disease that has required systemic treatment in the past 2 years. * has an active infection requiring systemic therapy. * inability to comply with study and follow-up procedures. * has had a severe hypersensitivity reaction (grade ≥3) to treatment with pembrolizumab, another monoclonal antibody, or has history of any hypersensitivity to any components of the study treatments or any of their excipients. * has received prior systemic anticancer therapy including investigational agents within 4 weeks (or, if shorter, within 5 half-lives for kinase inhibitors) prior to first dose of study treatment. * has received prior radiotherapy within 2 weeks of start of study treatment or has had a history of radiation pneumonitis. * receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment. * has received previous treatment with another agent targeting the il-2, il-7, or il-15 receptors. * is expected to require any other form of antineoplastic therapy while on study
influenza vaccine elicited immune response in immunocompromised patients

Conditions: Influenza Vaccine; Immunocompromised Patients

Summary: this study aims to understand how well influenza vaccines work in some individuals with weakened immune systems compared to healthy individuals. some people, such as those with hiv, multiple sclerosis, certain cancers, or autoimmune conditions, have more severe influenza disease courses due to their medical treatments. these individuals may also respond less effectively to vaccines. by comparing immune responses to the influenza vaccine in both immunocompromised patients and healthy participants, this study aims to identify patterns in vaccine effectiveness and side effects. the goal is to find better ways to predict vaccine response in vulnerable patients and improve protection against influenza.

the study is a single-center, prospective cohort study evaluating influenza vaccine responses in adults with weakened immune systems compared to healthy adults. immunocompromised participants include individuals with hiv, multiple sclerosis, rheumatological diseases, and b-cell malignancies after car-t cell therapy. all participants will receive a standard influenza vaccine, as recommended in switzerland, with immune response measured through blood tests at specific time points before and after vaccination. the primary objective is to compare influenza vaccine antibody levels in immunocompromised and healthy participants to determine if immune responses are different in the former group. secondary objectives include examining vaccine-induced immune cell activity, side effects, and the immune profile before vaccination in each patient subgroup. the study will also analyze gut microbiome differences between responders and non-responders and develop prediction models for vaccine effectiveness based on immune and demographic data. by doing so, researchers hope to enhance the understanding of how best to protect immunocompromised patients against influenza.

Eligibility criteria:
inclusion criteria: * ≥ 18 years old * diagnosed with rheumatological diseases on immunosuppressive therapies, or multiple sclerosis on immune modulating therapies, or b-cell malignancies after car-t cell therapy, or o plwh with cd4 cell count \>200/ul, or non-immunocompromised individuals attending the university clinic for infectious diseases to receive influenza vaccination. * provided written informed consent. exclusion criteria: * for people living with hiv: untreated or ≥2 measured viral loads above 50cp/ml in preceding 6 months * for non-immunocompromised controls: any inborn or acquired condition resulting in immunosuppression. * receiving b-cell depleting therapies in last 12 months for ms, ra patients and plwh * receipt of immunoglobulin-therapy (ivig) ≤4 months prior to the drawing of study samples * \< 18 years old * lack of written informed consent

Keywords: influenza immunocompromised vaccination vaccine car-t
comparison of different treatment methods in patella chondromalacia

Conditions: Knee Injuries

Summary: chondromalacia patella (cmp) is a common condition in patients presenting to healthcare units with anterior knee pain (1).

patellofemoral pain syndrome (pfps) is the most common type of pain in runners with a prevalence of 17%; it is limited to the anterior knee or the area behind the patella between the edges of the patella. although pfps and cmp are often considered to be the same disease, there is still controversy about the subject. it is caused by decreased quadriceps muscle strength, change in mechanical loading, lower limb kinematics and differentiation in muscle activation patterns during running .

Eligibility criteria:
inclusion criteria: * 18-65 years of age. * being diagnosed with chondromalacia * participate in the work on a voluntary basis * obtaining informed consent from them exclusion criteria: * fracture, ligament or muscle tear in the lower extremity within the last 3 months. * having a systemic disease * having a serious injury in the last 3 months
school response to families who have children with cancer

Conditions: Carcinomas; Squamous Cell Carcinoma; Adenocarcinoma

Summary: the purpose of this research is to investigate school response to families who have children with cancer. it is anticipated that the results of this study will enhance the support that schools can give to the population of families who have a child with cancer. the study will involve the parents in these families, the principal and an educator in the school of the child with cancer. measurement tools will include surveys, interviews, and other relevant educational and medical documents.


Eligibility criteria:
inclusion criteria: * patients will not be recruited. only parents, the school principals and the teachers will be recruited. * subjects will be 15 sets of parents who have had school-age children treated for cancer within the last 5 years.

Keywords: carcinomas (including squamous cell and adenocarcinoma)
epidemiology of lupus nephritis in nephrology unit in assiut university hospital

Conditions: Lupus Nephritis

Summary: study epidemiology of lupus nephritis patients admitted to nephrology unit inward or in outpatient clinic in assiut nephrology unit

this study are: to describe socio-demographic characteristics of lupus nephritis patients in nephrology unit of assiut university hospital ( old and new cases). to determine the associated risk factors in the study population to describe the clinical, laboratory characteristics, treatment modalities of lupus nephritis patients in nephrology unit of assiut university hospital ( old and new cases) to identify outcomes of treatment of these cases within 2 years according to different classes to evaluate the effectiveness of (type of interventions mentioned) among those patients.

Eligibility criteria:
inclusion criteria: * all patients admitted to nephrology unit or visiting the outpatient nephrology clinic,previously or newly diagnosed with lupus nephritis. exclusion criteria: * incomplete criteria for diagnosis of systemic lupus or presence of associated renal disease.
rl-1 novel human-derived bio-artificial liver treatment in patients of hbv related aclf

Conditions: Hepatitis B; Acute-On-Chronic Liver Failure

Summary: this study is to investigate the clinical efficacy and safety of rl-1 novel human-derived bio-artificial liver treatment in patients with hepatitis b virus related acute-on-chronic liver failure.

hepatitis b virus (hbv) related acute-on-chronic liver failure (aclf) is a serious condition with high mortality rate in china. but there still lacks of effective therapies in treatment of hbv related aclf, except liver transplantation. rl-1 novel human-derived bio-artificial liver treatment may be an effective and safe therapy due to the previous clinical data. this study is to investigate the clinical efficacy and safety of rl-1 novel human-derived bio-artificial liver treatment in patients with hbv related aclf.

Eligibility criteria:
inclusion criteria: 1. positive hepatitis b surface antigen or hepatitis b virus dna \> 0.5 year; 2. age from 18 to 65 years old; 3. serum total bilirubin level \> 10 times upper limit of normal; 4. prothrombin time activity \< 40% and ≥30%； 5. platelets \> 50\*10 e9/l. exclusion criteria: 1. other active liver diseases; 2. hepatocellular carcinoma or other malignancy; 3. pregnancy or lactation; 4. human immunodeficiency virus infection or congenital immune deficiency diseases; 5. severe diabetes, autoimmune diseases; 6. other important organ dysfunctions; 7. severe complications including severe infection, gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome; 8. patients can not follow-up; 9. investigator considering inappropriate.

Keywords: hepatitis b virus acute-on-chronic liver failure artificial liver
anaerobic antibiotic usage for pneumonia in the medical intensive care unit

Conditions: Pneumonia

Summary: observation of prescription usage of anaerobic antibiotics for patients admitted to the icu with pneumonia.

pneumonia is a common admitting diagnosis in the intensive care unit (icu). when aspiration is suspected, antibiotics to cover anaerobes are frequently used , but in the absence of clear risk factors, current guidelines have questioned their role. it is unknown how frequently these guidelines are followed.

Eligibility criteria:
inclusion criteria: * icu patients with diagnosis of pneumonia exclusion criteria: * patients with abdominal infections such as c diff.
the possible range of no.12a lymph node dissection of locally advanced gastric cancer

Conditions: Gastric Cancer; No.12a Lymph Node Dissection

Summary: the main purpose of this study is to evaluate the reasonable range of no.12a lymph node dissection of locally advanced gastric cancer.


Eligibility criteria:
inclusion criteria: * ≥ 18 and ≤ 75 years of age; preoperative gastric cancer patients with pathologically confirmed; had been treated with radical resection (d2, r0) of gastric cancer (lymph node≥16); willing and able to comply with the program during the study period; physical condition and organ function allows to tolerable abdominal surgery; written informed consent provided; under radical laparoscopic distal subtotal gastrectomy with more than a 6-month life expectancy; no other serious concomitant diseases; sufficient organ functions; no previous history of chemotherapy or radiotherapy; clinical stage: t2-4anxm0; karnofsky performance status (kps)\>60; eastern cooperative oncology group performance status (ecog): 0-1. exclusion criteria: * pregnancy or breast feeding; patients with serious liver disease (such as cirrhosis, etc.), kidney disease, respiratory disease or uncontrolled diabetes, hypertension and other chronic systemic diseases, heart disease with clinical symptoms, such as congestive heart failure, coronary heart disease symptoms, drug is difficult to control arrhythmia, hypertension, or six months had a myocardial infarction attack, or cardiac insufficiency; organ transplantation patients need immunosuppressive therapy; severe recurrent infections were not controlled or with other serious concomitant diseases; patients got other primary malignant tumors (except curable skin basal cell carcinoma and cervical cancer in situ) except gastric cancer within 5 years; psychiatric disease which require treatment; have the history of organ transplantation; within 6 months before study starts and in the process of this study, patients participate in other clinical researches.
a pharmacogenomic study of candesartan in heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate the impact of genetic variations on the response to candesartan in patients with heart failure who are already treated with an ace inhibitor.


Eligibility criteria:
principal inclusion criteria: 1. male or female \> or = 18 years old. 2. symptomatic chf corresponding to nyha class ii-iv symptoms for at least 4 weeks prior randomization. 3. lvef \< or = 40% 4. treatment with an optimal and stable dose of ace inhibitor for at least 4 weeks prior to enrolment in the study. principal exclusion criteria: 1. treatment with an arb within 8 weeks prior to randomization. 2. known hypersensitivity to arbs or ace inhibitors. 3. creatinine clearance \ 221 4. current serum potassium \> or = 5.0 mmol/l or a history of marked ace inhibitor or arb induced hyperkalemia. 5. known bilateral renal artery stenosis. 6. current symptomatic hypotension and/or systolic b.p. \< 90 mmhg. 7. decompensated heart failure described as hospitalization or i.v. administration of medication in emergency room or heart failure clinic within 4 weeks 8. stroke, acute coronary syndrome, pci within the last 4 weeks before randomization. 9. connective tissue disease or chronic inflammatory condition 10. acute inflammatory process such as an infection or gout attack in the last 2 weeks. 11. pregnant or lactating women or women of childbearing potential who are not protected from pregnancy by an accepted method of contraception.

Keywords: heart failure gene polymorphism candesartan ace inhibitors bnp pharmacogenomics
calypso knee system clinical sub-study, ous continued evaluation

Conditions: Osteoarthritis, Knee

Summary: calypso knee system clinical study, ous for subjects with symptomatic osteoarthritis of the medial compartment of the knee. the sub-study will achieve continued evaluation of the safety and clinical effectiveness of the calypso knee system.

this sub-study will be a single-arm, prospective, multi-center sub-study for continued evaluation of the safety and clinical effectiveness of calypso knee system using an additional measure of post-operative activity improvement.

Eligibility criteria:
inclusion criteria: 1. participants age - 25 to 65 years 2. body mass index (bmi) of \< 35, weight \< 300 lbs 3. knee osteoarthritis pain on the inner side of knee that has continued after at least 6 months of non-operative treatment exclusion criteria: 1. symptoms of osteoarthritis in the other knee or in lateral (outer) or patellofemoral compartments of the target knee 2. knee ligament or meniscal instability 3. other bone or joint conditions such as rheumatoid arthritis, paget's disease, charcot's disease or general conditions such as allergy or hypersensitivity to certain metals, active infection, certain neurological conditions, use of medication such as steroids or chemotherapy that could impact study participation or results
daily wear comparison of enhanced and non-enhanced silicone hydrogel lenses

Conditions: Myopia

Summary: the purpose of this study is to compare an experimental contact lens with a currently marketed contact lens.


Eligibility criteria:
inclusion criteria: * able to wear contact lenses for a minimum of 5 days a week, at least 8 hours a day * on exam have ocular findings that are considered normal and would not prevent the safe wear of contact lenses * other protocol-defined inclusion/exclusion criteria may apply exclusion criteria: * requires concurrent ocular medication * eye injury or surgery within twelve weeks immediately prior to enrollment * evidence of systemic or ocular abnormality, infection, or disease likely to affect successful wear of contact lenses or use of their accessory solutions * any active corneal infection * any use of medications for which contact lens wear would be contraindicated * history of corneal refractive surgery * wears toric contact lenses * other protocol-defined inclusion/exclusion criteria may apply